<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588571</url>
  </required_header>
  <id_info>
    <org_study_id>Sosudi2</org_study_id>
    <nct_id>NCT04588571</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Comparison of the Open Surgical and Endovascular Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee, TASC II, Type D.</brief_title>
  <official_title>Efficacy and Safety Comparison of the Open (Femoral-popliteal Proximal Bypass) and Endovascular (Recanalization With Angioplasty and Stenting With Biomimetic Interwoven Nitinol Stent) Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee, TASC II, Type D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endovascular revascularization and open bypass grafting above the knee show comparable&#xD;
      results in primary 2-year patency (about 65%) in medium-length lesions - TASC II, C (Pereira&#xD;
      et al, 2006). At the same time, a recent study, where the authors studied the effectiveness&#xD;
      of stenting of long lesions (200 mm or more) of the chronic occlusions of the femoropopliteal&#xD;
      segments (TASC II, D), showed unsatisfactory results (primary patency 45%) of the stented&#xD;
      segment within 2 years (Lin et al, 2015). One of the possible solutions to the problem of&#xD;
      breakage of stents in the femoral-popliteal position is a modified method of their&#xD;
      manufacture by braiding from nitinol wire. Some studies with intervowen nitinol stents did&#xD;
      show their resistance to breakage in this position. Moreover, the primary patency was &gt; 70%.&#xD;
      (Werner et al, 2014). These data suggest a better primary patency rate within 2 years with a&#xD;
      longer lesion length (&gt;200 mm).&#xD;
&#xD;
      This is a prospective, randomized, open-label study. The main objective of the study is to&#xD;
      compare the clinical efficacy and safety of two therapies for the treatment of prolonged&#xD;
      atherosclerotic lesions of the arteries of the femoropopliteal segment above the knee, TASC&#xD;
      II type D - femoropopliteal proximal shunting and recanalization with angioplasty and&#xD;
      stenting using biomimetic interwoven nitinol stent in patients with symptomatic peripheral&#xD;
      arterial disease at 24 months. Secondary objectives are to identify predictors of restenosis&#xD;
      and occlusions of the operating segment and compare the quality of life of patients after the&#xD;
      procedure. It is planned to recruit 110 patients (55 patients in each group). Observation&#xD;
      period 2 years. Primary endpoint:&#xD;
&#xD;
      -The effectiveness of the method of surgical treatment after 24 months (primary patency,&#xD;
      primary-assisted patency, secondary patency).&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Clinical efficacy of the method of surgical treatment after 24 months (MALE);&#xD;
&#xD;
        -  Safety of the method of surgical treatment in the early postoperative period (hematoma&#xD;
           of the surgical access area, peripheral neuropathy, purulent-infectious complications of&#xD;
           the surgical access area) and after 24 months (MACE);&#xD;
&#xD;
        -  Assessment of the quality of life in patients after surgical treatment at 6, 12, and 24&#xD;
           months (SF-36 questionnaire);&#xD;
&#xD;
        -  Evaluation of prognostic factors for adverse outcomes after surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endovascular revascularization and open bypass grafting above the knee show comparable&#xD;
      results in primary 2-year patency (about 65%) in medium-length lesions - TASC II, C (Pereira&#xD;
      et al, 2006). At the same time, a recent study, where the authors studied the effectiveness&#xD;
      of stenting of long lesions (200 mm or more) of the chronic occlusions of the femoropopliteal&#xD;
      segments (TASC II, D), showed unsatisfactory results (primary patency 45%) of the stented&#xD;
      segment within 2 years (Lin et al, 2015). One of the possible solutions to the problem of&#xD;
      breakage of stents in the femoral-popliteal position is a modified method of their&#xD;
      manufacture by braiding from nitinol wire. Some studies with interwoven nitinol stents did&#xD;
      show their resistance to breakage in this position. Moreover, the primary patency was &gt; 70%.&#xD;
      (Werner et al, 2014). These data suggest a better primary patency rate within 2 years with a&#xD;
      longer lesion length (&gt;200 mm).&#xD;
&#xD;
      This is a prospective, randomized, open-label study. The main objective of the study is to&#xD;
      compare the clinical efficacy and safety of two therapies for the treatment of prolonged&#xD;
      atherosclerotic lesions of the arteries of the femoropopliteal segment above the knee, TASC&#xD;
      II type D - femoropopliteal proximal shunting and recanalization with angioplasty and&#xD;
      stenting using biomimetic interwoven nitinol stent in patients with symptomatic peripheral&#xD;
      arterial disease at 24 months. Secondary objectives are to identify predictors of restenosis&#xD;
      and occlusions of the operating segment and compare the quality of life of patients after the&#xD;
      procedure.&#xD;
&#xD;
      The analysis of literature data showed, that two-year primary patency after endovascular&#xD;
      revascularization using a nitinol stent in long lesions was 60%. At the same time, the&#xD;
      two-year primary patency after the femoropopliteal proximal bypass was 56% (Enzmann et al.&#xD;
      Nitinol stent versus bypass in long femoropopliteal lesions: 2-year results of a randomized&#xD;
      controlled trial. JACC: Cardiovascular Interventions. 2019 Dec 23; 12 (24): 2541-9.).&#xD;
      Considering these data, it should be assumed that the use of biomimetic interwoven nitinol&#xD;
      stents will slightly improve the primary patency parameters within 2 years in the stenting&#xD;
      group. The 2-year primary patency after stenting of the femoropopliteal segment with an&#xD;
      interwoven nitinol stent was 76% (Scheinert et al., 2011). A power analysis was performed to&#xD;
      calculate the sample size of the &quot;non-inferiority&quot; design for a study power of 80%, a type 1&#xD;
      error probability of 5%, and a non-inferiority margin of 10%. It is planned to recruit 110&#xD;
      patients (55 patients in each group). The observation period of 2 years. Primary endpoint:&#xD;
&#xD;
      -The effectiveness of the method of surgical treatment after 24 months (primary patency,&#xD;
      primary-assisted patency, secondary patency).&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Clinical efficacy of the method of surgical treatment after 24 months (MALE);&#xD;
&#xD;
        -  Safety of the method of surgical treatment in the early postoperative period (hematoma&#xD;
           of the surgical access area, peripheral neuropathy, purulent-infectious complications of&#xD;
           the surgical access area) and after 24 months (MACE);&#xD;
&#xD;
        -  Assessment of the quality of life in patients after surgical treatment at 6, 12, and 24&#xD;
           months (SF-36 questionnaire);&#xD;
&#xD;
        -  Evaluation of prognostic factors for adverse outcomes after surgical treatment.&#xD;
           Screening It is performed in patients with a verified diagnosed occlusive lesion of the&#xD;
           femoropopliteal segment above the knee joint (type D according to the TASC II&#xD;
           classification), with chronic ischemia of the lower extremities of 3-6 categories&#xD;
           according to Rutherford.&#xD;
&#xD;
             -  Assessment of inclusion/exclusion criteria&#xD;
&#xD;
             -  Assigning a patient number&#xD;
&#xD;
      Study inclusion Collecting baseline information about the patient (history, including&#xD;
      information about concomitant therapy, data from the initial physical examination, ultrasound&#xD;
      data of the lower limb arteries, CT -arteriography data, assessment of the quality of life&#xD;
      using the SF-36 questionnaire. Randomization using the envelope method to one group or&#xD;
      another.&#xD;
&#xD;
      Group 1: Femoropopliteal proximal bypass; Group 2: Recanalization of prolonged occlusion of&#xD;
      the arteries of the femoral-popliteal segment above the knee joint with angioplasty and&#xD;
      stenting with a biomimetic interwoven nitinol stent.&#xD;
&#xD;
      Follow up period; 6, 12, and 24 months.&#xD;
&#xD;
      Performed:&#xD;
&#xD;
      Triplex ultrasound of one lower limb (restenosis, thrombosis, stent breakage);&#xD;
&#xD;
        -  Leg's roentgenography for the stenting group in two projections, for patients in whom a&#xD;
           stent breakage is suspected according to ultrasound;&#xD;
&#xD;
        -  Consultation with a cardiovascular surgeon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, randomized, open-label study. Group 1 (n=55): Femoropopliteal proximal bypass. Group 2 (n=55): Recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary patency</measure>
    <time_frame>24 months</time_frame>
    <description>primary patency is defined as absence of occlusion or flow-limiting stenosis (peak systolic velocity [PSV] ratio &gt;2.5) of the treated segment including 1 cm proximal and distal of the anastomosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary assisted patency</measure>
    <time_frame>24 months</time_frame>
    <description>primary assisted patency is defined as a secondary procedure is performed to prevent failure (in a flow-limiting stenosis [PSV ratio &gt;2.5] in a still-patent segment of stent or bypass, including the anastomoses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>secondary patency</measure>
    <time_frame>24 months</time_frame>
    <description>secondary patency is defined as a secondary procedure performed for graft or stent occlusion in an afterward patent vessel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MALE</measure>
    <time_frame>24 months</time_frame>
    <description>Major adverce limb events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the surgical treatment in the early postoperative period</measure>
    <time_frame>30 days</time_frame>
    <description>hematoma of the surgical access area, peripheral neuropathy, purulent-infectious complications of the surgical access area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>24 months</time_frame>
    <description>major adverce cardiovascular events, deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>SF-36 questionary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Ischemia Limb</condition>
  <condition>Superficial Femoral Artery Occlusion</condition>
  <condition>Popliteal Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Endovascular treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients (n=55) with recanalization of the femoral-popliteal arterial segment (TASC II, type D) above the knee with a biomimetic braided nitinol stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients (n=55) with femoropopliteal proximal bypass with a prolonged atherosclerotic lesion of the femoropopliteal arterial segment (TASC II, type D).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent</intervention_name>
    <description>Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.&#xD;
Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months.</description>
    <arm_group_label>Endovascular treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femoropopliteal proximal bypass</intervention_name>
    <description>Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.&#xD;
Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time.</description>
    <arm_group_label>Open surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt; 18 years;&#xD;
&#xD;
          -  Symptomatic lesion (Rutherford category 3 - 6);&#xD;
&#xD;
          -  Atherosclerotic prolonged occlusive lesion of the femoropopliteal arterial segment&#xD;
             above the knee, classified by TASC II as type D, confirmed by computed tomography or&#xD;
             arteriography;&#xD;
&#xD;
          -  De novo lesion;&#xD;
&#xD;
          -  Patient informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old;&#xD;
&#xD;
          -  Potentially pregnant women;&#xD;
&#xD;
          -  Asymptomatic lesion;&#xD;
&#xD;
          -  Acute ischemia;&#xD;
&#xD;
          -  Not de novo lesion;&#xD;
&#xD;
          -  Severe comorbidity with a life expectancy of fewer than 2 years;&#xD;
&#xD;
          -  Contraindications to antiplatelet therapy (double antiplatelet therapy is required for&#xD;
             at least 2 months after the intervention);&#xD;
&#xD;
          -  Patient participation in another clinical trial;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrey A Karpenko, PHD, MD</last_name>
    <phone>+79139504100</phone>
    <email>andreikarpenko@rambler.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meshalkin Research Institute of Pathology of Circulation</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirsk Area</state>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey –ê Karpenko, PHD, MD</last_name>
      <phone>+79139504100</phone>
      <email>andreikarpenko@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander A Gostev, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interwoven nitinol stent</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>prolonged occlusion of SFA</keyword>
  <keyword>endovascular treatment</keyword>
  <keyword>femoro-popliteal bypass</keyword>
  <keyword>TASC II, type D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

